frequenc
seriou
advers
event
compar
group
evalu
effect
ifn
therapi
prevent
ebola
viru
diseas
progress
andor
resolut
diseas
assess
effect
diseas
symptom
surviv
clinic
improv
evalu
compar
follow
paramet
group
day
treatment
centr
day
symptom
manifest
hemorrhag
ifn
may
caus
fever
myalgia
sore
throat
headach
nausea
vomit
diarrhea
similar
associ
ebola
viru
infect
advers
event
record
use
analysi
efficaci
phase
iii
intervent
trial
design
assess
safeti
trend
clinic
cours
ebola
viru
diseas
patient
year
age
treat
either
ifn
usual
support
care
usual
support
care
associ
appropri
monitor
therapi
plan
sampl
size
pilot
treatment
specimen
collect
schedul
durat
followup
subcutan
inject
ifn
daili
day
blood
sampl
drawn
day
one
month
discharg
treatment
centr
subject
follow
durat
stay
treatment
centr
first
patient
enrol
last
patient
last
visit
expect
studi
last
month
recombin
ifn
inject
steril
suspens
licens
provid
singl
use
syring
steril
clear
colorless
preservativefre
liquid
singleus
syring
composit
ml
microgram
mcg
ml
ifn
preffil
glass
syring
contain
mcg
ifn
mg
sodium
acet
trihydr
usp
mg
glacial
acet
acid
usp
mg
arginin
hydrochlorid
usp
mg
polysorb
water
inject
usp
ph
subcutan
sc
inject
undilut
lot
number
inclus
criteria
potenti
patient
fulfil
follow
criteria
elig
trial
enrol
abl
provid
inform
consent
substitut
decis
maker
may
provid
inform
consent
case
patient
ill
unabl
provid
inform
consent
age
year
year
age
day
inclus
treatment
centr
suspect
probabl
confirm
ebola
viru
infect
per
case
definit
symptom
onset
day
abl
compli
trial
procedur
treat
physician
respons
recommend
initi
therapi
ifn
special
accesscompassion
releas
program
potenti
subject
fulfil
follow
criteria
exclud
random
control
trial
enrol
known
hypersensit
interferon
beta
prepar
pregnanc
use
ifn
associ
arbortifaci
effect
rhesu
monkey
may
caus
miscarriag
human
chronic
liver
diseas
synthet
dysfunct
andor
decompens
ascit
hepat
encephalopathi
histori
bleed
oesophag
gastric
varic
moder
sever
congest
heart
failur
chf
grade
iii
iv
left
ventricular
function
previou
histori
seriou
psychiatr
ill
eg
psychosi
suicid
ideat
andor
attempt
depress
requir
hospit
histori
sever
activ
autoimmun
diseas
system
lupu
erythematosu
thyroid
vascul
precaut
reconsid
casebycas
basi
patient
ill
weigh
risk
benefit
ifn
therapi
presenc
underli
condit
exclus
criteria
review
treat
physician
assess
potenti
risk
therapi
special
accesscompassion
releas
program
follow
consid
precaut
temporari
contraind
sinc
condit
exacerb
administr
ifn
howev
correct
andor
control
prior
administr
ifn
result
exclus
potenti
particip
thrombocytopenia
platelet
bleed
disord
contraind
sc
inject
neutropenia
absolut
neutrophil
count
anemia
hemoglobin
uncontrol
seizur
moder
sever
uncontrol
hypertens
clinic
gout
precaut
review
treat
physician
assess
potenti
risk
therapi
special
accesscompassion
releas
program
endpoint
describ
compar
baselin
day
treatment
group
use
crosstabul
tabl
fisher
exact
test
categor
variabl
ttest
normal
distribut
continu
variabl
wilcoxon
nonparametr
test
nonnorm
distribut
continu
ordin
variabl
data
collect
compar
retrospect
analysi
agematch
ebolainfect
individu
present
similar
symptom
viral
load
receiv
ifn
safeti
variabl
fever
consid
three
differ
format
ordin
repres
variou
level
sever
ae
instanc
fever
describ
none
mild
moder
sever
binari
consid
presenc
vs
absenc
ae
binari
consid
seriou
express
ae
instanc
group
moder
sever
togeth
separ
analys
time
period
day
conduct
time
period
sever
report
ae
particip
count
advers
event
seriou
advers
event
consid
two
way
presenc
event
presenc
event
relat
treatment
viral
clearanc
symptom
endpoint
analyz
binari
variabl
detect
presenc
nondetect
absenc
well
continu
variabl
applic
eg
quantit
rtpcr
measur
clinic
ebola
hemorrhag
fever
character
onset
fever
headach
myalgia
fatigu
gastrointestin
distress
day
post
exposur
viru
immun
respons
play
critic
role
ebola
viru
ebov
pathogenesi
infect
associ
earli
loss
lymphocyt
downregul
interferon
product
action
subsequ
dysregul
coagul
lead
clinic
import
hemorrhag
minor
patient
genu
ebolaviru
includ
differ
virus
sudan
viru
tai
forest
viru
ebov
reston
viru
bundibugyo
viru
ebov
highest
fatal
rate
data
human
infect
ebov
limit
evid
previou
outbreak
suggest
innat
immun
respons
predict
outcom
specif
earli
transient
proinflammatori
cytokin
respons
includ
associ
surviv
yet
sustain
increas
proinflammtori
cytokin
respons
dendrit
cell
infect
abrog
ifn
respons
associ
death
notabl
absenc
robust
innat
immun
respons
includ
activ
dendrit
cell
adapt
immun
respons
b
cell
activ
sever
impair
lead
failur
control
viral
replic
poor
outcom
context
outbreak
first
outbreak
west
africa
therefor
lack
understand
within
local
commun
lack
experi
among
health
care
worker
limit
capac
rapid
respons
high
level
commun
exposur
consequ
household
care
customari
burial
procedur
lead
fear
panic
resist
propos
respons
measur
close
commun
tie
across
border
area
impact
careseek
behavior
contact
trace
magnitud
spread
outbreak
affect
countri
novemb
rural
area
larg
citi
see
tabl
requir
enorm
commit
resourc
robust
sustain
respons
capac
vaccin
specif
approv
treatment
ebov
diseas
current
avail
present
time
patient
provid
usual
support
care
arriv
treatment
centr
promis
data
relat
novel
vaccin
potenti
antivir
drug
deriv
vitro
preclin
anim
model
ebov
infect
yet
evalu
safeti
efficaci
human
current
context
recommend
ethic
offer
unproven
intervent
unknown
efficaci
unknown
advers
event
potenti
treatment
prevent
strategi
therapeut
intervent
must
administ
inform
consent
freedom
choic
decis
made
follow
thorough
riskbenefit
assess
respect
confidenti
digniti
patient
addit
moral
oblig
collect
share
data
gener
understand
safeti
efficaci
intervent
includ
moral
duti
evalu
intervent
best
possibl
clinic
trial
feasibl
inform
futur
intervent
candid
antivir
therapeut
intervent
also
evalu
includ
antivir
agent
may
target
viru
directli
may
target
host
function
requir
viral
life
cycl
andor
may
augment
host
defens
except
usfdaapprov
drug
consid
repurpos
antivir
ebov
diseas
antivir
agent
consid
develop
actual
treatment
dose
regimen
uncertain
current
time
mechan
action
individu
agent
dictat
tempor
usag
earli
vs
late
stage
diseas
zmapp
leafbio
produc
tobacco
plant
tripl
monoclon
antibodi
cocktail
mechan
action
neutral
viru
kill
infect
cell
nonhuman
primat
studi
reveal
treatment
efficaci
treatment
initi
day
viru
infect
control
human
safeti
data
product
current
avail
human
convalesc
serum
limit
nonhuman
primat
efficaci
studi
data
suggest
passiv
transfer
may
provid
partial
protect
isar
protocol
convalesc
plasma
collect
administr
develop
avail
feasibl
administr
convalesc
serum
locationdepend
ie
avail
infrastructur
collect
process
screen
brincidofovir
chimerix
small
molecul
viral
polymeras
inhibitor
demonstr
vitro
antivir
activ
filovirus
metabol
differ
evalu
macaqu
nonhuman
primat
preclud
phase
studi
trial
subject
conduct
cmv
adenoviru
infect
potenti
treatment
cours
current
avail
oral
bioavail
given
nausea
vomit
diarrhea
concern
tablet
treatment
cours
recombin
nematod
anticoagul
protein
block
factor
x
cleavag
complet
phase
trial
drug
exhibit
efficaci
initi
hour
infect
nonhuman
primat
dose
current
avail
depend
ongo
stabil
test
drotrecogin
alfa
approv
treatment
sever
sepsi
withdrawn
nonhuman
primat
studi
show
treatment
efficaci
administ
hour
infect
avail
unknown
given
poor
avail
logisticsfeas
surround
administr
candid
intervent
evalu
repurpos
approv
drug
evalu
advantag
includ
avail
clinic
experi
drug
briefli
includ
clomiphenetoremifen
select
estrogen
receptor
modul
may
effect
late
viral
entri
demonstr
vitro
efficaci
also
afford
surviv
administ
hour
infect
mice
howev
nonhuman
primat
studi
identifi
ocular
disturb
result
studi
suspend
advers
event
investig
vitro
screen
librari
drug
identifi
number
candid
includ
ion
channel
inhibitor
kinas
inhibitor
antiparasit
drug
antiinflammatori
drug
howev
addit
studi
need
evalu
potenti
intervent
ebov
diseas
interferon
ifn
classifi
type
type
ii
type
iii
type
ifn
mediat
divers
biolog
effect
includ
larg
speciesspecif
cell
typeindepend
antivir
respons
sever
cell
typerestrict
respons
immunolog
relev
ifn
modul
b
lymphocyt
respons
promot
prolifer
memori
cell
promot
differenti
cell
induc
secret
cell
promot
isotyp
switch
b
cell
differenti
plasma
cell
upregul
mhc
class
moreov
ifn
activ
macrophag
activ
enhanc
cytotox
nk
cell
regul
matur
termin
differenti
dendrit
cell
ifn
widespread
potenti
therapeut
agent
treatment
viral
infect
current
administ
chronic
hepat
b
c
hcv
infect
ifn
inhibit
viral
infect
prevent
viral
entri
target
cell
block
differ
stage
viral
replic
cycl
differ
virus
type
ifn
critic
role
link
innat
adapt
immun
respons
viral
challeng
regul
activ
cytokin
receptor
includ
receptor
etc
chemokin
chemokin
receptor
express
occur
earliest
nonspecif
respons
viral
infect
mediat
activ
microbi
pattern
recognit
receptor
includ
tlr
cytoplasm
receptor
preced
cytokin
inde
virus
evolv
immun
evas
strategi
specif
target
ifn
respons
confirm
import
ifn
antivir
immun
evas
strategi
relev
one
consid
ifn
treatment
ebov
infect
experiment
data
indic
ebov
protein
inhibit
host
cell
system
lead
ifn
product
also
inhibit
event
associ
ifn
respons
ebov
effect
block
product
either
rigi
inde
specif
effector
molecul
ifn
respons
shown
directli
inhibit
ebov
entri
cell
releas
viral
progeni
cell
effect
prevent
viral
spread
treat
ebov
infect
individu
ifn
may
therefor
overrid
inhibitori
effect
ebov
infect
ifn
product
challeng
remain
administ
treatment
earli
postexposur
viral
burden
ifn
respons
would
disabl
approv
usfda
treatment
aidsrel
kaposi
sarcoma
hepat
b
combin
ribavirin
differ
prepar
infergen
approv
usfda
hepat
c
infect
current
evalu
hiv
infect
estim
sustain
virolog
respons
hcv
genotyp
genotyp
use
pegyl
combin
ribavirin
provid
evid
therapeut
benefit
antivir
also
shown
antiinflammatori
effect
decreas
cell
prolifer
increas
circul
level
thu
demonstr
clinic
role
treat
viral
diseas
vitro
inhibit
ebov
replic
see
figur
inhibit
type
ifn
signal
increas
filoviru
sever
notabl
rhesu
macaqu
administ
antibodi
one
ifn
receptor
subunit
day
viru
inocul
increas
viremia
earlier
progress
death
ifn
therapi
rhesu
macaqu
start
hour
viru
inocul
continu
day
prolong
time
death
ebov
start
hour
post
viru
inocul
daili
day
led
surviv
marv
infect
therapi
cynomolog
macaqu
x
iukg
im
start
hour
viru
inocul
daili
reduc
viremia
adenoviru
express
enhanc
protect
efficaci
mab
nhp
administ
onset
symptom
notabl
nonhuman
primat
studi
either
adenovir
vectoredinfergen
gene
administ
consider
may
account
limit
therapeut
benefit
observ
challeng
dose
ebov
pfu
intramuscular
rout
inocul
rout
inocul
significantli
high
lethal
challeng
dose
may
distinguish
cours
infect
nonhuman
primat
compar
current
human
ebov
diseas
note
ill
nonhuman
primat
rapid
progress
lethal
seen
human
ifn
dose
contrast
current
dose
therapeut
efficaci
hcv
multipl
sclerosi
regimen
employ
publish
nonhuman
primat
studi
order
fold
greater
mgkg
rais
issu
invok
advers
event
may
undermin
potenti
therapeut
benefit
dose
might
reflect
use
human
ie
surviv
may
compromis
studi
differ
innat
adapt
immun
respons
nonhuman
primat
human
rhesu
subtyp
homolog
correspond
human
sequenc
other
partial
homolog
human
term
agonist
mediat
distinct
type
ifn
respons
human
nonhuman
primat
vitro
vivo
differ
cytokin
profil
human
nonhuman
primat
also
exist
nonhuman
primat
sensit
vaccin
human
ifn
amino
acid
glycoprotein
molecular
weight
approxim
dalton
produc
recombin
dna
technolog
use
genet
engin
chines
hamster
ovari
cell
human
interferon
beta
gene
introduc
amino
acid
sequenc
ifn
ident
natur
human
ifn
use
world
health
organ
intern
standard
interferon
studi
drug
specif
activ
approxim
million
intern
unit
antivir
activ
per
mg
ifn
determin
use
vitro
cytopath
effect
bioassay
use
lung
carcinoma
cell
encephalomyocard
viru
emcv
mcg
contain
approxim
million
intern
unit
antivir
activ
use
method
activ
standard
known
comparison
activ
biogenidec
ifn
ifn
appropri
differ
refer
standard
assay
use
measur
activ
data
publish
unpublish
nonhuman
primat
studi
suggest
ifn
treatment
may
effect
reduc
viremia
prolong
surviv
avail
prefil
syring
ifn
addit
follow
support
choic
ifn
like
member
type
ifn
famili
ifn
shown
protect
cell
viru
infect
well
show
efficaci
hcvinfect
individu
moreov
use
treat
hcv
europ
us
natur
nonrecombin
use
extens
japan
indic
data
suggest
hcv
use
treat
diseas
safeti
toler
favor
addit
known
antivir
activ
ifn
hcv
antivir
activ
ebolainfect
rhesu
macaqu
avonex
favor
safeti
toler
profil
ms
patient
approxim
million
person
year
exposur
worldwid
biogenidec
inc
data
file
clinic
effect
avonex
patient
relaps
form
multipl
sclerosi
ms
studi
two
random
multicent
doubleblind
placebocontrol
studi
patient
ms
studi
safeti
efficaci
treatment
avonex
year
studi
studi
patient
receiv
either
mcg
avonex
placebo
intramuscular
inject
weekli
patient
receiv
inject
year
continu
follow
studi
complet
two
hundr
eightytwo
patient
complet
year
studi
patient
complet
year
studi
patient
treat
avonex
year
patient
month
patient
year
patient
definit
diagnosi
multipl
sclerosi
least
year
durat
least
exacerb
year
prior
studi
entri
per
year
durat
diseas
less
year
entri
studi
particip
without
exacerb
prior
month
kurtzk
expand
disabl
statu
scale
edss
score
rang
edss
scale
quantifi
disabl
patient
ms
rang
normal
neurolog
exam
death
due
ms
patient
chronic
progress
multipl
sclerosi
exclud
studi
primari
outcom
assess
time
progress
disabl
measur
increas
edss
score
least
point
sustain
least
month
increas
edss
score
reflect
accumul
disabl
endpoint
use
help
distinguish
perman
increas
disabl
transient
increas
due
exacerb
time
onset
sustain
progress
disabl
significantli
longer
avonextr
patient
placebotr
patient
studi
p
percentag
patient
progress
end
year
placebotr
patient
avonextr
patient
repres
rel
reduct
risk
accumul
disabl
avonextr
group
compar
placebotr
group
distribut
confirm
edss
chang
studi
entri
baselin
end
studi
examin
statist
signific
differ
avonex
placebo
group
confirm
chang
patient
least
schedul
visit
p
rate
frequenc
ms
exacerb
secondari
outcom
patient
includ
studi
irrespect
time
studi
annual
exacerb
rate
per
year
avonextr
group
per
year
placebotr
group
p
avonex
treatment
significantli
decreas
frequenc
exacerb
subset
patient
enrol
studi
least
year
placebotr
patient
avonextr
patient
p
gadolinium
gd
enhanc
magnet
reson
imag
mri
scan
brain
obtain
patient
baselin
end
year
treatment
secondari
outcom
includ
gdenhanc
lesion
number
volum
lesion
volum
gdenhanc
lesion
seen
brain
mri
scan
repres
area
breakdown
blood
brain
barrier
thought
secondari
inflamm
avonextr
patient
demonstr
significantli
lower
gdenhanc
lesion
number
year
treatment
placebotr
patient
p
volum
gdenhanc
lesion
show
similar
treatment
effect
avonex
placebo
group
p
percentag
chang
lesion
volum
studi
entri
year
significantli
lower
avonextr
placebotr
patient
p
signific
differ
lesion
volum
chang
seen
studi
entri
year
avonex
placebo
group
exact
relationship
mri
find
clinic
statu
ms
patient
unknown
prognost
signific
mri
find
studi
evalu
studi
patient
recent
experienc
isol
demyelin
event
involv
optic
nerv
spinal
cord
brainstemcerebellum
lesion
typic
multipl
sclerosi
brain
mri
receiv
either
mcg
avonex
n
placebo
n
intramuscular
inject
weekli
patient
enrol
studi
twoyear
period
follow
three
year
develop
second
clinic
exacerb
anatom
distinct
region
central
nervou
system
studi
primari
outcom
measur
time
develop
second
exacerb
anatom
distinct
region
central
nervou
system
time
develop
second
exacerb
significantli
delay
avonextr
compar
placebotr
patient
p
kaplanmei
estim
percentag
patient
develop
exacerb
within
month
placebo
group
avonex
group
rel
rate
develop
second
exacerb
avonex
group
rate
placebo
group
confid
interv
safeti
consider
ifn
depress
suicid
psychot
disord
hepat
injuri
monitor
liver
function
test
monitor
patient
sign
symptom
hepat
injuri
consid
discontinu
ifn
hepat
injuri
occur
anaphylaxi
allergicreact
discontinu
occur
congest
heart
failur
monitor
patient
preexist
signific
cardiac
diseas
worsen
cardiac
symptom
decreas
peripher
blood
count
monitor
complet
blood
count
autoimmun
disord
consid
discontinu
ifn
new
autoimmun
disord
occur
common
advers
reaction
least
frequent
avonex
placebo
flulik
symptom
includ
chill
fever
myalgia
asthenia
alcohol
swab
skin
prior
venipunctur
ifn
inject
use
steril
dispos
needl
syring
minim
risk
infect
appli
pressur
needl
punctur
site
minim
bruis
also
carri
exclus
patient
previous
experienc
sever
allerg
reaction
ifn
prepar
sinc
particip
probabl
remain
treatment
centr
durat
treatment
train
personnel
avail
case
allerg
reaction
postinject
first
ten
ebolainfect
subject
receiv
ifn
stagger
administr
schedul
use
minim
effect
unforeseen
seriou
advers
event
patient
popul
second
patient
administ
ifn
first
subject
receiv
five
dose
likewis
third
subject
administ
ifn
second
subject
receiv
dose
opinion
treat
physician
special
access
program
conakri
guinea
unforeseen
seriou
advers
event
observ
five
day
tenth
subject
receiv
ifn
one
remain
subject
enrolledto
enrol
studi
may
receiv
first
dose
ifn
day
studi
offer
potenti
antivir
therapi
patient
ebov
diseas
although
ifn
administ
patient
ebov
infect
clinic
experi
ifn
anoth
viru
hcv
demonstr
favor
safeti
profil
thu
major
benefit
studi
may
help
patient
sever
ebov
diseas
recov
rapidli
prevent
complic
prevent
death
risk
studi
accept
consid
known
safeti
profil
investig
product
potenti
benefit
patient
high
yield
favor
riskbenefit
ratio
trial
conduct
investig
conakri
guinea
centr
select
base
interest
particip
abil
conduct
trial
studi
hypothesi
ifn
therapi
reduc
viral
load
ebolainfect
subject
ifn
safe
use
individu
complic
associ
ebov
infect
prevent
ifn
consequ
inhibit
viral
replic
primari
object
pilot
studi
evalu
effect
ifn
viremia
peripher
blood
ebolainfect
subject
secondari
object
evalu
safeti
ifn
ebolainfect
subject
tertiari
object
determin
whether
ifn
prevent
ebola
viri
diseas
progress
andor
resolut
diseas
studi
singlearm
clinic
trial
preand
poststudi
design
studi
includ
patient
admit
ebov
infect
treatment
centr
patient
meet
inclus
criteria
give
inform
consent
inform
consent
given
substitut
decis
maker
respons
patient
due
patient
ill
patient
enrol
studi
ie
first
elig
patient
enrol
patient
receiv
ifn
treat
special
accesscompassion
releas
program
consent
treatment
treat
physician
administ
conakri
guinea
part
studi
collect
data
retrospect
includ
result
research
test
residualto
discard
blood
sampl
studi
team
make
avail
systemat
data
collect
form
treat
physician
help
monitor
advers
event
effect
therapi
enabl
specif
report
special
access
program
administ
conakri
guinea
treat
physician
patient
receiv
ifn
note
retrospect
data
collect
includ
patient
ebov
diseas
particip
clinic
trial
data
ifn
patient
match
data
patient
receiv
ifn
base
age
sex
estim
day
postonset
symptom
viral
load
avail
data
collect
similar
propos
protocol
also
protocol
propos
test
blood
collect
clinic
residu
discard
comparison
group
intervent
studi
author
approv
treat
physician
access
ifn
treatment
patient
special
access
program
base
medic
decis
treatment
discuss
treat
physician
patient
patient
substitut
decis
maker
collect
safeti
efficaci
data
monitor
treat
physician
report
dr
kader
kond
done
base
studi
case
report
facilit
report
treat
physician
allow
specif
consist
report
dr
kader
kond
compon
studi
provid
abil
special
access
ifn
indic
clinic
provid
consist
monitor
advers
event
effect
therapi
consid
patient
may
continu
deterior
despit
antivir
may
infect
antivir
resist
strain
ifn
made
avail
treat
physician
patient
treat
physician
believ
may
benefit
give
ifn
consent
treatment
ifn
would
obtain
treat
physician
monitor
treatment
import
ensur
safeti
concern
identifi
monitor
includ
collect
inform
patient
chart
well
research
test
residu
sampl
would
otherwis
discard
templat
inform
consent
form
attach
comparison
group
group
patient
ebov
diseas
receiv
ifn
note
recogn
like
miss
data
studi
particip
due
retrospect
data
collect
collect
data
base
clinic
cours
intervent
requir
care
patient
patient
suspect
probabl
confirm
ebov
infect
identifi
admit
particip
treatment
centr
goal
identifi
potenti
particip
earli
possibl
provid
time
inform
consent
process
follow
cours
diseas
avoid
delay
ifn
therapi
anticip
mani
potenti
particip
receiv
ifn
ill
consid
earli
therapi
ifn
may
benefici
later
intervent
delay
administr
could
detriment
particip
follow
definit
use
conduct
studi
one
clinic
find
ill
associ
histori
least
one
follow
symptom
temperatur
c
f
andor
potenti
patient
fulfil
follow
criteria
elig
enrol
intervent
trial
abl
provid
inform
consent
substitut
decis
maker
may
provid
inform
consent
case
patient
ill
unabl
provid
inform
consent
age
year
year
age
day
inclus
admit
treatment
centr
suspect
probabl
confirm
ebov
infect
defin
symptom
onset
day
abl
compli
trial
procedur
potenti
patient
fulfil
follow
criteria
exclud
studi
enrol
known
hypersensit
interferon
beta
prepar
pregnanc
use
ifn
associ
arbortifaci
effect
rhesu
monkey
may
caus
miscarriag
human
chronic
liver
diseas
synthet
dysfunct
andor
decompens
ascit
hepat
encephalopathi
histori
bleed
esophag
gastric
varic
moder
sever
congest
heart
failur
grade
iii
grade
iv
lv
function
previou
histori
seriou
psychiatr
ill
eg
psychosi
suicid
depress
requir
hospit
admiss
histori
sever
autoimmun
diseas
system
lupu
erythematosu
thyroid
vascul
intervent
studi
exclus
criteria
review
treat
physician
assess
potenti
risk
therapi
follow
consid
precaut
temporari
contraind
sinc
condit
exacerb
administr
ifn
howev
correct
andor
control
prior
administr
ifn
result
exclus
potenti
particip
correct
andor
control
prior
administr
ifn
becom
exclus
criteria
clinic
gout
precaut
reconsid
casebycas
basi
patient
ill
weigh
risk
benefit
ifn
therapi
presenc
underli
condit
observ
studi
precaut
review
treat
physician
assess
potenti
risk
therapi
studi
undertaken
guinea
clinic
trial
particip
substitut
decis
maker
must
understand
sign
inform
consent
document
guinean
physician
associ
health
worker
play
import
role
address
cultur
ethic
sensit
associ
treatment
protocol
guinean
author
indic
assum
respons
dissemin
inform
natur
clinic
trial
aim
treat
ebola
viru
diseas
observ
part
studi
collect
data
retrospect
result
research
test
residualto
discard
blood
sampl
respiratori
secret
comparison
group
part
studi
part
popul
may
includ
exist
epidemiolog
studi
waiver
consent
patient
comparison
group
enrol
studi
waiver
consent
appli
reason
effort
made
obtain
inform
consent
individu
data
use
howev
note
obtain
inform
consent
nonifn
patient
surviv
ebola
infect
left
clinic
may
difficult
obtain
may
rel
nonifn
patient
die
follow
ebola
infect
retrospect
data
collect
test
consist
possibl
clinic
trial
data
collect
form
depend
data
avail
medic
record
research
test
perform
blood
secret
sampl
residu
discard
inform
consent
sign
prior
initi
therapi
elig
confirm
data
eg
demograph
may
collect
retrospect
patient
chart
sourc
document
demograph
collect
particip
undergo
evalu
review
medic
histori
record
chart
andor
obtain
particip
famili
member
physic
examin
perform
studi
physician
one
treat
physician
chart
record
case
report
form
patient
current
clinic
statu
also
document
prestudi
screen
baselin
investig
occur
prefer
day
signatur
inform
consent
definit
prior
initi
treatment
ifn
state
perform
day
hospit
day
x
ill
followup
data
also
record
basi
comparison
relev
time
point
amongst
particip
treat
ifn
expect
elig
particip
treat
within
hour
admit
treatment
centr
earlier
therapi
ifn
cours
diseas
ill
like
offer
highest
chanc
potenti
benefit
prevent
deterior
day
mention
investig
note
refer
day
ifn
therapi
andor
followup
hospit
patient
discharg
prior
day
initi
therapi
possibl
seen
medic
studi
followup
month
postiniti
treatment
everi
effort
made
combin
clinic
care
followup
studi
followup
data
avail
medic
chart
collect
given
outbreak
limit
health
care
resourc
avail
differ
treatment
centr
baselin
investig
resourcedepend
may
includ
fevertemperatur
measur
pcr
determin
viremia
clinic
evalu
sever
symptom
chill
myalgia
sore
throat
cough
nausea
diarrhea
hemorrhag
ifn
obtain
biogenidec
inc
cambridg
usa
dosag
follow
million
iu
sc
day
administr
follow
product
monograph
gener
done
patient
nurs
treatment
centr
ifn
dose
may
decreas
problem
toler
million
iu
million
iu
well
toler
dose
may
remain
may
reincreas
million
iu
maximum
million
per
day
dose
adjust
treat
physician
respons
durat
treatment
may
shorter
day
case
patient
recov
rapidli
minimum
day
therapi
decis
stop
ifn
therapi
case
made
patient
treat
physician
gener
patient
expect
discontinu
treatment
upon
discharg
treatment
centr
hour
prior
discharg
observ
deterior
treatment
patient
expect
admit
least
day
due
natur
ill
patient
need
discontinu
prior
day
therapi
rational
document
casebycas
basi
concomit
medic
appropri
determin
treat
physician
document
crf
instanc
discret
treat
physician
broadspectrum
antibiot
may
also
given
cover
possibl
superimpos
bacteri
infect
collect
daili
record
undertaken
either
prospect
retrospect
assess
advers
event
efficaci
therapi
day
st
day
treatment
day
weekli
admit
treatment
centr
day
post
last
dose
patient
therapi
discontinu
prior
day
assess
follow
schedul
allow
comparison
diseas
cours
follow
record
permit
start
immedi
prior
onset
administr
ifn
daili
basi
whilst
patient
treatment
centr
temperatur
fever
defin
temperatur
concurr
ill
symptom
chill
myalgia
cough
sore
throat
nausea
vomit
diarrhea
hemaorrhag
advers
event
record
per
protocol
medic
histori
baselin
daili
record
blood
sampl
cc
blood
virolog
measur
feasibl
convalesc
serum
cc
tiger
top
tube
obtain
month
possibl
note
expect
miss
data
point
studi
particip
depend
clinic
care
data
avail
medic
chart
residu
blood
sampl
avail
test
interferon
ifn
famili
natur
occur
protein
produc
eukaryot
cell
respons
viral
infect
biolog
agent
three
major
type
interferon
defin
type
ifnalpha
beta
epsilon
kappa
omega
type
ii
ifngamma
type
iii
ifnlambda
interferonbeta
member
type
subset
interferon
type
interferon
consider
overlap
also
distinct
biolog
activ
bioactiv
ifn
includ
ifnbeta
induc
via
bind
specif
receptor
surfac
human
cell
differ
bioactivit
induc
three
major
subtyp
ifn
like
reflect
differ
signal
transduct
pathway
induc
signal
cognat
receptor
interferon
beta
exert
biolog
effect
bind
receptor
chian
surfac
human
cell
bind
initi
complex
cascad
intracellular
event
lead
express
numer
interferoninduc
gene
product
marker
includ
synthetas
microglobulin
neopterin
product
measur
serum
cellular
fraction
blood
collect
patient
treat
ifn
clinic
studi
conduct
multipl
sclerosi
patient
show
interleukin
level
cerebrospin
fluid
increas
patient
treat
ifn
compar
placebo
serum
level
maxim
increas
hour
intramuscular
inject
ifn
remain
elev
week
howev
relationship
establish
absolut
level
clinic
outcom
multipl
sclerosi
pharmacokinet
avonex
multipl
sclerosi
patient
evalu
pharmacokinet
pharmacodynam
profil
ifn
healthi
subject
follow
dose
mcg
microgram
investig
serum
level
ifn
measur
antivir
activ
slightli
detect
limit
follow
mcg
subcutan
dose
increas
higher
dose
subcutan
dose
serum
level
ifn
gener
peak
hour
postdos
rang
hour
declin
rate
consist
rang
hour
elimin
halflif
biolog
respons
marker
eg
neopterin
microglobulin
induc
ifn
follow
parenter
dose
microgram
microgram
healthi
subject
treat
patient
biolog
respons
marker
level
increas
within
hour
dose
remain
elev
least
day
peak
biolog
respons
marker
level
typic
observ
hour
dose
relationship
serum
ifn
level
level
induc
biolog
respons
marker
mechan
ifn
exert
effect
multipl
sclerosi
unknown
prefil
syring
ifn
steril
liquid
inject
ml
mcgml
ifn
prefil
glass
syring
contain
mcg
ifn
mg
sodium
acet
trihydr
usp
mg
glacial
acet
acid
usp
mg
arginin
hydrochlorid
usp
mg
polysorb
water
inject
usp
ph
approxim
dose
titrat
devic
suppli
biogen
idec
enabl
half
dose
ml
million
iu
administ
full
dose
syring
dose
reduct
requir
expect
diseas
continu
progress
initi
hour
therapi
stabil
improv
anticip
manifest
day
consid
potenti
advers
event
ifn
therapi
special
consider
place
determin
whether
treatment
regimen
advers
affect
diseas
progress
particip
progress
hour
treat
ifn
term
worsen
diseas
symptom
progress
felt
treat
physician
probabl
relat
treatment
regimen
ifn
either
decreas
dose
discontinu
expect
ifn
direct
antivir
effect
initi
earli
cours
ill
immunomodulatori
effect
exagger
inflammatori
respons
observ
ill
patient
like
drug
caus
certain
flulik
symptom
symptom
compat
diseas
progress
unlik
symptom
seriou
short
concern
ifn
associ
worsen
diseas
may
dosereduc
treatment
stop
section
extract
product
monograph
supplementari
inform
provid
section
protocol
side
effect
list
base
phase
studi
ifn
given
three
time
week
week
sinc
ifn
given
day
studi
safeti
inform
list
section
day
therapi
may
relev
common
advers
event
avonex
report
placebocontrol
studi
im
administr
list
incid
placebotr
multipl
sclerosi
patient
list
first
avonextr
multipl
sclerosi
patient
list
second
headach
flulik
symptom
pain
asthenia
fever
chill
abdomin
pain
inject
site
pain
infect
inject
site
inflamm
chest
pain
inject
site
reaction
toothach
depress
dizzi
upper
respiratori
tract
infect
sinus
bronchiti
nausea
myalgia
arthralgia
urinari
tract
infect
urin
constitu
abnorm
alopecia
eye
disord
inject
site
ecchymosi
anemia
migrain
vasodil
symptom
may
occur
follow
viru
infect
may
difficult
know
whether
due
administr
ifn
patient
underli
condit
sever
psychiatr
advers
event
may
develop
person
receiv
therapi
ifn
includ
suicid
ideat
suicid
risk
happen
small
less
occas
exacerb
preexist
cardiovascular
diseas
caus
angina
chest
pain
rhythm
disturb
heart
attack
myocardi
infarct
person
known
preexist
heart
diseas
physician
monitor
cardiac
symptom
close
discontinu
ifn
cardiovascular
symptom
appear
worsen
drug
ifn
rare
associ
ophthalm
problem
includ
retin
hemorrhag
optic
neuriti
papilledema
person
longterm
treatment
particip
ask
report
physician
disturb
vision
treatment
ifn
may
exacerb
liver
diseas
discontinu
grade
hepatotox
rare
ifn
associ
pulmonari
syndrom
includ
pneumonia
worsen
asthma
particip
develop
worsen
pulmonari
symptomatolog
felt
due
ifn
drug
dosereduc
stop
ifn
may
aggrav
autoimmun
diseas
exampl
system
lupu
rheumatoid
arthriti
preexist
autoimmun
diseas
close
monitor
manag
advers
event
gener
achiev
dose
reduct
ifn
howev
case
lifethreaten
advers
event
develop
cardiac
dysfunct
precipit
declin
pulmonari
function
hour
period
explain
diseas
progress
may
associ
ifn
therapi
discontinu
flulik
symptom
treat
acetaminophen
mg
ibuprofen
mg
minut
ifn
inject
follow
guidelin
use
determin
dose
modif
investig
product
advers
event
implement
grade
life
threaten
advers
event
sae
ifn
discontinu
advers
event
ae
untoward
medic
occurr
patient
clinic
investig
particip
administ
product
necessarili
causal
relationship
treatment
ae
therefor
unfavor
unintend
sign
includ
abnorm
laboratori
find
exampl
symptom
diseas
tempor
associ
use
medicin
product
whether
consid
relat
medicin
product
advers
event
record
transcrib
crf
solicit
ae
nonsolicit
ae
collect
daili
first
four
day
everi
day
therapi
whenev
report
patient
sae
collect
studi
medic
day
administr
last
dose
fatal
lifethreaten
result
persist
signific
disabilityincapac
requir
initi
hospit
prolong
exist
hospit
caus
congenit
anomali
birth
defect
term
lifethreaten
refer
event
patient
risk
death
time
event
refer
event
hypothet
might
caus
death
sever
death
occur
protocol
therapi
within
day
last
dose
report
see
sae
must
report
within
hour
studi
coordin
enabl
report
guinean
ministri
health
within
calendar
day
identif
sae
must
also
report
within
hour
biogenidec
inc
clinicaltrialsteam
biogenideccom
fax
ae
sae
evalu
investig
deleg
causal
relationship
investig
product
safeti
assess
compar
occurr
sae
clinic
import
advers
event
moder
sever
attribut
intervent
safeti
monitor
intervent
studi
involv
collect
data
direct
comparison
ifn
patient
receiv
ifn
studi
stop
rule
patient
die
therapi
result
sae
assess
relat
investig
product
virolog
clearanc
clearanc
andor
reduct
viral
rna
day
day
determin
pcr
andor
quantit
real
time
pcr
thu
presenc
viru
sampl
score
posit
day
number
copi
compar
evalu
viru
clearanc
therapi
time
viru
becom
undetect
safeti
occurr
sever
advers
event
time
onset
durat
number
day
sever
serious
solicit
nonsolicit
inject
site
reaction
system
advers
event
occur
day
last
inject
occurr
natur
time
onset
rel
first
ifn
dose
durat
sever
relationship
inject
sae
throughout
trial
frequenc
clinic
import
moder
sever
advers
event
compar
group
frequenc
seriou
advers
event
compar
group
paramet
look
advers
event
solicit
local
inject
site
erythema
swell
fever
heart
rate
blood
pressur
rash
clinic
improv
evalu
compar
follow
paramet
group
incid
fever
persist
durat
incid
durat
symptom
ill
chill
myalgia
sore
throat
cough
nausea
vomit
diarrhea
hemorrhag
death
caus
studi
durat
monitor
clinic
cours
consist
oppos
look
effect
ifn
casebycas
basi
provid
addit
inform
guid
indic
therapi
epidem
provid
detail
surveil
data
public
health
emerg
expect
sampl
size
pilot
clinic
trial
prove
feasibl
studi
includ
patient
suspect
proven
infect
ebov
admit
treatment
centr
sampl
size
chosen
assess
feasibl
run
clinic
trial
set
larg
number
patient
also
feasilibti
treat
larg
number
patient
success
larger
clinic
trial
may
feasibl
demograph
underli
condit
describ
mean
standard
deviat
continu
variabl
median
interquartil
rang
ordin
count
variabl
frequenc
percentag
categor
variabl
endpoint
describ
compar
treatment
usual
standard
care
group
use
crosstabul
tabl
fisher
exact
test
categor
variabl
ttest
normal
distribut
continu
variabl
wilcoxon
nonparametr
test
nonnorm
distribut
continu
ordin
variabl
safeti
variabl
fever
consid
three
differ
format
ordin
repres
variou
level
sever
symptom
instanc
fever
describ
none
mild
moder
sever
binari
consid
presenc
vs
absenc
symptom
binari
consid
seriou
express
symptom
instanc
group
moder
sever
togeth
separ
analys
time
period
day
conduct
time
period
sever
report
ae
particip
count
advers
event
seriou
advers
event
consid
two
way
presenc
event
presenc
event
relat
treatment
symptom
assess
repeat
measur
use
gee
model
surviv
analyz
use
kaplanmei
curv
coxproport
hard
model
week
month
surviv
rate
determin
viral
clearanc
analyz
binari
variabl
detect
presenc
nondetect
absenc
well
continu
variabl
applic
eg
quantit
rtpcr
measur
data
manag
includ
design
crf
design
databas
well
data
entri
assur
data
integr
assum
investig
deleg
crf
possibl
append
particip
clinic
chart
direct
document
treat
physician
nurs
plan
accommod
data
collect
transcript
context
limit
resourc
outbreak
particip
may
withdraw
studi
time
reason
without
jeopardi
current
futur
care
investig
may
also
withdraw
patient
studi
without
particip
permiss
event
intercurr
ill
advers
event
treatment
failur
protocol
violat
administr
reason
reason
reason
withdraw
clearli
document
crf
specif
criteria
prematur
discontinu
treatment
also
includ
progress
diseas
due
ifn
grade
iv
advers
event
felt
due
ifn
reason
remov
patient
studi
advers
event
abnorm
laboratori
result
princip
specif
event
test
document
complet
crf
particip
withdrawn
time
opinion
investig
studi
particip
would
best
interest
particip
particip
may
withdraw
withdrawn
treatment
automat
lead
withdraw
rest
studi
particip
would
continu
follow
per
protocol
safeti
diseas
cours
therapi
unnecessari
withdraw
patient
avoid
case
particip
fail
present
followup
examin
document
reason
effort
ie
document
phone
call
certifi
mail
undertaken
locat
recal
least
determin
health
statu
fulli
respect
particip
right
effort
document
particip
sourc
document
crf
investig
classifi
termin
statu
particip
end
studi
termin
page
crf
accord
follow
particip
withdraw
advers
event
relat
ifn
follow
deem
appropri
investig
resolut
event
chronic
event
establish
case
advers
event
relat
ifn
particip
follow
deem
appropri
investig
document
deem
sourc
document
indic
crf
event
loss
followup
loss
followup
procedur
follow
note
particip
may
withdrawn
investig
product
therapi
continu
follow
accord
protocol
clinic
cours
andor
provid
addit
blood
respiratori
secret
specimen
research
test
studi
may
discontinu
administr
reason
new
data
investig
product
result
studi
becom
avail
andor
advic
regulatori
author
trial
prematur
termin
reason
investig
inform
studi
particip
time
fashion
assur
appropri
therapi
followup
amend
studi
made
without
consult
agreement
studi
sponsor
includ
manufactur
ifn
ie
biogenidec
inc
rel
rapidli
effort
make
avail
extend
studi
possibl
larger
multicentr
intern
studi
part
treatment
armamentarium
earli
possibl
initi
result
pilot
trial
determin
extend
extens
particip
per
protocol
whether
larger
multicent
studi
appropri
determin
factor
safeti
possibl
small
sampl
size
trend
toward
efficaci
compar
standard
care
regimen
addit
effect
treatment
regimen
viral
detect
examin
